Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sutura announces June date for shareholder complaint hearing:

This article was originally published in Clinica

Executive Summary

Vascular suturing device manufacturer Sutura has announced that the terms of an out-of-court settlement with Synapse Funds, Go Industries and other plaintiffs will be heard on June 1 2007. The hearing will take place in the Superior Court of California and will draw a conclusion to an ongoing dispute between plaintiffs and Sutura over its merger with Technology Visions in 2005. Both Go and Synapse sought injunctive relief to prevent the consummation of pending merger, whereas Go also called for the removal of Anthony Nobles and Egbert Ratering from the Sutura board of directors. The Fountain Valley, California-based company said the settlement would allow it to focus more time on developing its SuperStitch and HeartStitch product lines and also to complete its task of finding new strategic business partners.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT048385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel